Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-826-4 | CAS number: 127-19-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- 13-14 pregnant rabbits per group; exposure restricted to gestation days (GD) 7-19
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
- Report date:
- 1989
- Reference Type:
- publication
- Title:
- Inhalation developmental toxicity in rabbits on dimethylacetamide with cover letter
- Author:
- BASF Corp.
- Year:
- 1 989
- Bibliographic source:
- TSCATS OTS0535030
- Reference Type:
- publication
- Title:
- Developmental toxicity of dimethylacetamide in rabbits following inhalation exposure
- Author:
- Klimisch HJ & Hellwig J
- Year:
- 2 000
- Bibliographic source:
- Human Exp Toxicol 19: 676-683
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- 13-14 pregnant rabbits per group; exposure restricted to gestation days (GD) 7-19
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- N,N-dimethylacetamide
- EC Number:
- 204-826-4
- EC Name:
- N,N-dimethylacetamide
- Cas Number:
- 127-19-5
- Molecular formula:
- C4H9NO
- IUPAC Name:
- N,N-dimethylacetamide
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- - Name of test material: dimethylacetamide (DMAC)
- Source: BASF AG
- Purity: 99.9%
- Batch No.: 86/104
No further details available.
Test animals
- Species:
- rabbit
- Strain:
- other: Russian
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Dr. Karl Thomae GmbH, Biberach/Riss, Germany
- Mean body weight at initiation: 2.3 kg
- Age at initiation: 23-27 weeks old
- Acclimation period: Prior to artificial insemination
- Housing: Individually
- Certified diet and tap water: ad libitum (water and diet analysed for contaminations, negative results)
ENVIRONMENTAL CONDITIONS:
- Temperature: 20-24 °C
- Humidity: 30-70 %
- Photoperiod: 12 hours dark/12 hours light
Administration / exposure
- Route of administration:
- inhalation
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- air
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION /EXPOSURE PARAMETERS
The animals were adapted to exposure conditions (air without test substance) at gestation days 1-4.
Vapourisation was performed at a temperature of 50, 60, or 65°C (low, mid, and high dose, respectively) in an evaporator resulting in a mixture with air (50 % relative air humidity, 22 °C; compressed air in high dose group); the vapour-air-mixture was discharged into the exposure chamber (ca. 1.1 m³). There was negative pressure for treatment groups and positive pressure for the control group. Technical parameters of exposure (temperature, pressure, air humidity, air flow) were controlled. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Measurement of total hydrocarbon by GC technique (calibrated); daily intermittend sampling.
Temperature (23.5, 24.7, 24.6, 25.3 °C at 0, 0.2, 0.7, 2 mg/L) and relative air humidity (53 %) were kept constant. - Details on mating procedure:
- - Impregnation procedure: Artificial insemination
- Duration of treatment / exposure:
- Gestation days (GD) 7-19
- Frequency of treatment:
- Daily for 6 h/day
- Duration of test:
- GD 29
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0.2 mg/L air (analytical)
- Remarks:
- ± 0.01 mg/l (SD). 0.2 mg/l (nominal concentration).
- Dose / conc.:
- 0.7 mg/L air (analytical)
- Remarks:
- ± 0.01 mg/l (SD). 0.7 mg/l (nominal concentration).
- Dose / conc.:
- 2 mg/L air (analytical)
- Remarks:
- ± 0.06 mg/l (SD). 2.0 mg/l (nominal concentration).
- No. of animals per sex per dose:
- Initial 15 rabbits per group.
In satellite groups (control and high dose) 5 pregnant rabbits. - Control animals:
- yes, concurrent no treatment
- Details on study design:
- Dose selection rationale: No details
Examinations
- Maternal examinations:
- CLINICAL SIGNS, MORTALITY:
Clinical signs were recorded daily during, prior and after exposure (mortality).
BODY WEIGHT:
Body weight was measured on GD 3, 7, 10, 13, 16, 19, 21, 24, 27 and 29.
Corrected body weight gain was measured (substracting uterus weight).
GROSS PATHOLOGY:
At termination a necropsy was performed.
OTHER:
In satellite groups (control and high dose; n=5) additional clinical chemistry parameters were assessed (blood sampling at GD 20) and histopathology of the liver was performed; clinical chemistry parameters included alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, inorganic phosphate, calcium, glucose, total protein, bilirubin, triglyceride. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination.
Examinations included:
- Gravid uterus weight
- Number of corpora lutea
- Number of implantations
- Number of resorptions (temporally differenciated), dead and living fetuses - Fetal examinations:
- Fetal weight, sex, viability and placental weight were recorded (fetal length was not measured .
Retardations and variations were recorded as well as malformations, based on:
- External examinations
- Soft tissue examinations
- Skeletal examinations (via x-rays)
- Head examinations (12 transversal sections after fixation in Bouin's solution) - Statistics:
- WILLIAMS test
FISHER exact test
KRAUTH test
NOVA-DUNNETTS test
Level of significance: p<0.05
Clinical chemistry: KRUSKAL-WALLIS, MANN-WHITNEY U-Tests - Indices:
- See results
- Historical control data:
- Yes
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Description (incidence):
- There was one abort in the low dose group on GD 23 (dam sacrificed).
- Body weight and weight changes:
- no effects observed
- Gross pathological findings:
- no effects observed
Maternal developmental toxicity
- Pre- and post-implantation loss:
- no effects observed
- Dead fetuses:
- no effects observed
- Other effects:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were effects on mean uterus weight (increased at 0.2 mg/l and 0.7 mg/l level) related to the low number of fetuses in the control group (compared to historical controls). Furthermore, placental weight was reduced in treatment groups, but this effects was also related to the reduced number of living fetuses in the control group (see also placental weight/litter).
In each group one rabbit was not pregnant (conception rate 93.3 % in all groups).
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEC
- Effect level:
- 2 mg/L air
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- clinical signs
- mortality
- Dose descriptor:
- NOAEC
- Effect level:
- 2 mg/L air
- Based on:
- test mat.
- Basis for effect level:
- dead fetuses
- pre and post implantation loss
Maternal abnormalities
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- 2.0 mg/l: Reduced fetal and placental weights were observed.
0.7 mg/l: Effects on fetal weight in these dose groups were considered not to be of toxicological relevance (low number of fetuses in control group and increased litter weight in treatment groups) - Changes in sex ratio:
- no effects observed
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- 2.0 mg/l: Increased variations (skeletal variations of ribs, sternum and vertebral column; separated origin of the carotids; also increased compared to historical controls) were observed.
0.7 mg/l: Increased skeletal variations, e.g. sternebrae fused and accessory ribs, both outside historical range, but no statistically significant increase in total skeletal variations. Increases in skeletal retardations (not dose related) were within the historical range. - Visceral malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- Increased malformations (not significant but uncommon in historical controls like malformations of the vasculature; increased incidence in defects of the septum) were considered by the authors to be treatment related.
Effect levels (fetuses)
- Dose descriptor:
- NOAEC
- Effect level:
- 0.2 mg/L air (analytical)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: increased skeletal variations
Fetal abnormalities
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- skeletal: rib
- other: skeletal: sternum, vertebral column; visceral: vasculature, defects of the septum
Overall developmental toxicity
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 700 mg/m³ air (analytical)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects in the absence of maternal toxicity effects
- Dose response relationship:
- no
Any other information on results incl. tables
Developmental toxicity in rabbits after inhalation exposure to N,N-dimethylacetamide
Data related to main groups
Parameter |
Vehicle control |
0.2 mg/L |
0.7 mg/L |
2 mg/L |
Pregnant rabbits |
14/15 |
14/15 |
14/15 |
14/15 |
Rabbits with abort |
- |
1 |
- |
- |
Implantations/dam |
6.0 |
6.92 |
7.50 |
6.71 |
Living fetuses/dam |
4.71 |
6.54 |
6.71 |
5.57 |
Dead implants/dam |
1.29 |
0.38 |
0.79 |
1.14 |
% post-implantation loss |
23.1 |
6.0 |
13.3 |
17.9 |
Placental weight m&f (g) |
4.94 |
4.23** |
4.22** |
4.03** |
Placental weight/litter (g) |
24.4 |
27.2 |
27.3 |
21.8 |
Litter weight (g) |
206.7 |
244.3 |
252.5 |
197.9 |
Fetal weight m and f (g) |
41.3 |
37.5* |
38.4* |
35.9** |
% fetuses/litter with soft tissue malformations |
6.4 |
2.1 |
3.2 |
13.6 |
% fetuses/litter with soft tissue variations |
48.4 |
30.4 |
40.9 |
85.0* |
% fetuses/litter with skeletal variations |
9.2 |
8.0 |
23.8 |
61.6** |
*: p<0.05; **: p<0.01
Applicant's summary and conclusion
- Conclusions:
- The NOAEC for developmental effects in rabbits after inhalation exposure was 0.7 mg/L and the LOAEC 2 mg/L; no maternal toxicity was found at dose levels up to 2 mg/L.
- Executive summary:
The test substance was investigated for its teratogenic potential in female Humalayan rabbits exposed by inhalation (study report of BG Chemie, 1989; published by Klimish and Hellwig, 2000). Fifteen animals per dose group and control group were used and exposed to 0.2, 0.7, and 2.0 mg/l (equivalent to 0, 57, 200 or 570 ppm) for 6 hours/day from GD7-19 and sacrified at GD29. Two satellite groups exposed to 0 or 2.0 mg/L with 5 animals per group were observed for clinical signs, lethality and body weight until GD20 and clinical chemistry, gross pathology and histopathological investigation of the liver were performed. Maternal animals of the main groups were observed for clinical signs, body weight, lethality, weight of uterus, gross pathology, implants, and corpora lutea. Fetuses were examined for number, weight, sex, weight of placenta, external observations, soft tissue observations including observations of the head, and skeletal observations.
Maternal toxicity was not obseved neither in main groups nor in satellite groups.
Fetotoxic effects were caused at a concentration of 0.7 mg/L (increased skeletal variations, e.g. fused sternebrae and accessory ribs), but there was no statistically significant increase in total skeletal variations. At 2.0 mg/L fetotoxic effects (e.g., significantly decreased fetal and placental weights, increase in soft tissue and skeletal variations) and also signs of a weak teratogenic effect expressed as a marginal, statistically not significant increase in soft tissue malformations (regarding the heart and great vessels) were observed. No compound-related effects were observed in the fetuses after exposure to 0.2 mg/l.
Thus, the highest concentration tested under these conditions (2.0 mg/1) was found to be a no-observable-adverse-effectlevel (NOAEL) for the maternal Himalayan rabbit, whereas 0.2 mg/L was defined as the NOAEL for the developing organism.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
